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Alzheimer’s disease (AD) in patients receiving stable donepezil
treatment compared with not providing memantine.
METHODS: Data from a U.S. multicenter randomised clinical
trial that compared memantine versus placebo in moderate to
severe AD patients on stable doses of donepezil was used to eval-
uate the cost effectiveness of providing memantine to donepezil.
Using methodology developed by Kurz et al., patients were clas-
siﬁed at each visit as dependent or non-dependent according to
their ADCS-ADL19 scores. Mean weekly costs were estimated
from the National Health Service and Personal Social Services
perspectives for patients with MMSE £14 that participated in a
UK epidemiological study—the LASER-AD study. QALYs per
dependency were estimated from a Danish Study. Per week mean
acquisition cost and effectiveness of treatment were £975;
0.6511 and £288; 0.3207 for dependent and non-dependent
patients. Total drug costs for the 24-week period were £492 for
donepezil and £937 for memantine plus donepezil. Costs,
QALYs and time of non-dependence were associated with each
dependency level and added to obtain total outcomes over the
24-week study period. RESULTS: Over the evaluation period,
memantine added to patients stabilised on donepezil was 
associated with an additional 0.0112 QALYs, an additional 
1.77 weeks of independence and a £771 cost reduction compared
with donepezil alone. The cost reduction is not statistically sig-
niﬁcant but suggests that clinical advantages offset some of the
cost of adding memantine. CONCLUSION: This analysis sug-
gests that memantine treatment provided to patients receiving
stable donepezil treatment is cost-effective compared with not
adding memantine. As costs and QALYs were assessed retro-
spectively, further prospective studies are required to support this
ﬁnding.
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OBJECTIVE: To determine persistence of treatment with
donepezil (DON), rivastigmine (RIV), galantamine (GAL) and
memantine (MEM) in patients with Alzheimer Dementia (AD)
in a Spanish population setting. METHODS: Retrospective AD
cohort study performed in nine Primary Care Health Centers
from four different Autonomous Communities (Andalucia,
Cantabria, Cataluña & Valencia) in Spain. Descriptive standard
analyses were performed. ANOVA and Chi-square tests were
used to show the differences among mean duration therapy and
treatment adherence after 52 weeks. A Kaplan-Meier survival
analysis was applied to assess overall pattern persistence after
three-year of follow up, and the log rank test was used for testing
signiﬁcance. RESULTS: A total of 299 patients (44.8% female),
mean age 77.88 years (SD: 6.32), were included; 101 DON
(34%), 105 RIV (35%), 51 GAL (17%) and 42 MEM (14%).
Mean treatment duration was slightly longer and signiﬁcant for
DON patients 83.3 weeks (95% CI: 72.7–93.9) than for the
other drugs: RIV; 76.6 (66.0–87.3), GAL; 65.8 (55.3–76.3),
MEM; 60.9 (48.8–73.1), p = 0.049. Treatment adherence after
52 weeks was numerically higher with DON (63%) than with
the other medications: RIV; 55%, GAL; 55%, and MEM; 52%,
p = 0.525. Overall persistence of treatment was signiﬁcantly
higher with DON [median time; 70.3 weeks (95% CI:
49.8–90.7)] than for the others drugs: RIV [56.1 weeks
(36.1–76.2)], GAL [56.7 weeks (41.1–72.3)] and MEM [52.1
weeks (35.2–69.1)], Log Rank = 10.16, p = 0.017. CONCLU-
SION: This retrospective study including Spanish AD patients
showed numerically differences on treatment adherence after one
year of therapy among the four antidementia medications com-
mercially available. The global treatment persistence during the
three-year follow up was signiﬁcantly higher in patients treated
with donepezil compared to those who received rivastigmine,
galantamine or memantine.
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OBJECTIVE: To estimate the overall burden of pediatric
epilepsy on the family and Irish health care system and to estab-
lish whether there is a relationship between epilepsy proﬁle and
this burden. METHOD: The sample was drawn from a popula-
tion of children with epilepsy attending a tertiary pediatric neu-
rology clinic in Dublin. Data was collected prospectively on
health care resource use and time lost from school and work.
Diary cards were completed at three monthly intervals.
RESULTS: Complete data was available on 127 children aged
15 months to 16.7 years (median 8.8), 54% were male and 52%
lived in a rural setting. A total of 61% had cryptogenic or symp-
tomatic epilepsy, 63% had partial seizures and 53% had frequent
seizures (>10 seizures/month). The annual cost of epilepsy was
signiﬁcantly higher for those with cryptogenic/symptomatic
epilepsy (€9248) and frequent seizures (€9145) relative to idio-
pathic epilepsy (€2600) and no/infrequent seizures (€3951) (P <
0.0001). Children with frequent seizures had a higher risk of
being hospitalised (P = 0.03) and lost more days at school (P <
0.0005). 50% of families contacted the pediatric liaison nurse,
and 12% made more than 5 contacts. Five percent of children
attended their GP while 37% of families had independently
sought complementary medicine. CONCLUSIONS: The eco-
nomic and social burden of pediatric epilepsy is substantial and
relates to the epilepsy syndrome and frequency of seizures. In
this prospective study a large dependence on epilepsy liaison
nurse support was found, an area that requires extra resources.
A large number of families also sought advice from non medical
sources.
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OBJECTIVES: The aim of this prospective study was to deter-
mine the relationship between seizure type, seizure frequency and
epilepsy syndrome on the quality of life of both the child and
family over a one year period. METHOD: The sample was
drawn from a population of children with epilepsy attending a
tertiary Paediatric Neurology service in Dublin. Data was col-
lected on seizure type and frequency, epilepsy syndrome, physi-
